[go: up one dir, main page]

BR9612318A - "métodos de tratamento com compostos tendo atividade especìfica ou seletiva sobre o receptor de raralfa" - Google Patents

"métodos de tratamento com compostos tendo atividade especìfica ou seletiva sobre o receptor de raralfa"

Info

Publication number
BR9612318A
BR9612318A BR9612318-4A BR9612318A BR9612318A BR 9612318 A BR9612318 A BR 9612318A BR 9612318 A BR9612318 A BR 9612318A BR 9612318 A BR9612318 A BR 9612318A
Authority
BR
Brazil
Prior art keywords
treatment
compounds
receptor
methods
rar
Prior art date
Application number
BR9612318-4A
Other languages
English (en)
Inventor
Min Teng
Tien T Duong
Roshantha A Chandraratna
Original Assignee
Vision Pharmaceuticals L P Soc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vision Pharmaceuticals L P Soc filed Critical Vision Pharmaceuticals L P Soc
Publication of BR9612318A publication Critical patent/BR9612318A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N25/00—Investigating or analyzing materials by the use of thermal means
    • G01N25/20—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity
    • G01N25/48—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation
    • G01N25/4846—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation for a motionless, e.g. solid sample
    • G01N25/4866—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation for a motionless, e.g. solid sample by using a differential method

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Combustion & Propulsion (AREA)
  • Obesity (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: <B>''MéTODOS DE TRATAMENTO COM COMPOSTOS TENDO ATIVIDADE ESPECìFICA OU SELETIVA SOBRE O RECEPTOR DE RAR~ ALFA''<B>. Os compostos retinóides, os quais atuam específica ou seletivamente sobre os subtipos de receptores de RAR~ 1<242>~ na preferência sobre os subtipos de receptores de RAR~ <225> e RSR~ 1~, possuem propriedades farmacêuticas desejáveis associadas com os retinóides, e são particularmente adequados para o tratamento de tumores, tais como a leucemia monocítica aguda, o carcinoma cervical, o mieloma, os carcionomas ovarianos e o carcinomas da cabeça e do pescoço, sem terem um ou mais efeitos colaterais indesejáveis dos retinóides, tal como induzimento da perda de peso, a toxicidade mucocutânea, a irritação da pele e a capacidade de teratogenia.
BR9612318-4A 1995-12-29 1996-12-16 "métodos de tratamento com compostos tendo atividade especìfica ou seletiva sobre o receptor de raralfa" BR9612318A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/580,553 US5965606A (en) 1995-12-29 1995-12-29 Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
PCT/US1996/020511 WO1997024116A2 (en) 1995-12-29 1996-12-16 METHODS OF TREATMENT WITH COMPOUNDS HAVING RARα RECEPTOR SPECIFIC OR SELECTIVE ACTIVITY

Publications (1)

Publication Number Publication Date
BR9612318A true BR9612318A (pt) 1999-12-28

Family

ID=24321568

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9612318-4A BR9612318A (pt) 1995-12-29 1996-12-16 "métodos de tratamento com compostos tendo atividade especìfica ou seletiva sobre o receptor de raralfa"

Country Status (16)

Country Link
US (4) US5965606A (pt)
EP (1) EP0869782A2 (pt)
JP (1) JP2000502707A (pt)
KR (1) KR19990076814A (pt)
CN (1) CN1211180A (pt)
AU (1) AU710483B2 (pt)
BR (1) BR9612318A (pt)
CA (1) CA2241758A1 (pt)
CZ (1) CZ206998A3 (pt)
HU (1) HUP0001643A3 (pt)
IL (1) IL125121A0 (pt)
MX (1) MX9805282A (pt)
NZ (1) NZ326155A (pt)
PL (1) PL327627A1 (pt)
RU (1) RU2191009C2 (pt)
WO (1) WO1997024116A2 (pt)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977125A (en) 1994-10-31 1999-11-02 Eisai Co., Ltd. Mono-or polyenic carboxylic acid derivatives
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
US5965606A (en) * 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
US20070213290A1 (en) * 1996-10-17 2007-09-13 Kingsman Alan J Neurite regeneration
US20040266715A1 (en) * 1999-03-31 2004-12-30 Wong Liang Fong Neurite regeneration
GB9907461D0 (en) * 1999-03-31 1999-05-26 King S College London Neurite regeneration
EP1025857A4 (en) * 1997-10-22 2003-11-12 Eisai Co Ltd RETINOIC ACID AGONISTS, PREVENTIVE AND THERAPEUTIC AGENTS FOR NEPHRITES
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
FR2776511B1 (fr) * 1998-03-31 2001-05-11 Galderma Rech Dermatologique Utilisation dans ou pour la preparation d'une composition d'au moins un inhibiteur de l'activite de l'acide retinoique
US6197798B1 (en) 1998-07-21 2001-03-06 Novartis Ag Amino-benzocycloalkane derivatives
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
PT1259484E (pt) 2000-01-18 2005-09-30 Novartis Ag Carboxamidas uteis como inibidores de proteina de transferencia de triglicerido microsomal e de secrecao de apolipoproteina b
EP1268835B1 (en) * 2000-03-30 2008-01-16 Oxford Biomedica (UK) Limited Retinoic acid receptor beta-2 and gene therapy vectors for the treatment of neurological disorders
TWI281911B (en) * 2000-04-04 2007-06-01 Allergan Inc Treatment of tumors with RARalpha selective retinoid compounds in combination with other anti-tumor agents
US6252090B1 (en) 2000-08-29 2001-06-26 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6380256B1 (en) * 2000-08-29 2002-04-30 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6369225B1 (en) 2000-08-29 2002-04-09 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
CA2420869A1 (en) * 2000-08-29 2002-03-07 Allergan, Inc. Compounds having activity as inhibitors of cytochrome p450rai
US6313107B1 (en) * 2000-08-29 2001-11-06 Allergan Sales, Inc. Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
US6387951B1 (en) 2000-08-29 2002-05-14 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
US6369261B1 (en) 2000-08-29 2002-04-09 Allergan Sales, Inc. Compounds having activity as inhibitors of cytochrome P450RAI
DE60136477D1 (de) * 2000-10-02 2008-12-18 Hoffmann La Roche Retinoide zur behandlung von emphysem
EP1935869A1 (en) * 2000-10-02 2008-06-25 F. Hoffmann-La Roche Ag Retinoids for the treatment of emphysema
JP2002131257A (ja) * 2000-10-26 2002-05-09 Nisshinbo Ind Inc 熱伝導率測定方法、測定装置及び断熱材の製造方法
US6843595B2 (en) * 2001-01-26 2005-01-18 Waters Investment Limited Differential scanning calorimeter accounting for heat leakage
JP2005511516A (ja) 2001-09-25 2005-04-28 スミスクライン ビーチャム コーポレーション 選択的ｒｘｒリガンド
US6740676B2 (en) * 2002-03-19 2004-05-25 Allergan, Inc. 4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-benzoic and 2-[4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-phenyl]-acetic acid, their esters and salts having cytochrome p450rai inhibitory activity
DE10227182B4 (de) * 2002-06-18 2013-01-31 Mettler-Toledo Ag Probenhalter für die Differenz-Thermoanalyse
US6620963B1 (en) 2002-09-19 2003-09-16 Allergan, Inc. TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-PHENYL AND TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-HETEROARYL AND RELATED COMPOUNDS HAVING RARα RECEPTOR SELECTIVE BIOLOGICAL ACTIVITY
EP1528392B1 (de) * 2003-10-28 2007-08-29 Mettler-Toledo AG Thermoanalytischer Sensor und Verfahren zu dessen Herstellung
US7077563B2 (en) * 2003-11-19 2006-07-18 General Electric Company Deposition sensor based on differential heat flux measurement
JP2007513880A (ja) 2003-11-25 2007-05-31 ノボ　ノルディスク　アクティーゼルスカブ 新規のサリチルアニリド
JP4884963B2 (ja) * 2004-03-10 2012-02-29 財団法人乙卯研究所 記憶固定促進剤
EP1717566A1 (de) * 2005-04-25 2006-11-02 Mettler-Toledo AG Thermoanalytischer Sensor
US20070060620A1 (en) * 2005-09-09 2007-03-15 John Sefton Use of RAR retinoid agonists to increase sperm count and sperm mobility in males
EP1937244B1 (en) 2005-09-30 2018-07-25 Io Therapeutics, LLC Treatment of cancer with specific rxr agonists
GB0605683D0 (en) * 2006-03-21 2006-05-03 Servomex Group Ltd Thermal conductivity sensor
US20080273572A1 (en) * 2006-06-02 2008-11-06 James Madison University Thermal detector for chemical or biological agents
JP4849961B2 (ja) * 2006-06-05 2012-01-11 エスアイアイ・ナノテクノロジー株式会社 熱分析装置
US7470057B2 (en) * 2006-08-24 2008-12-30 Waters Investments Limited Differential scanning calorimeter sensor and method
JP2008089474A (ja) * 2006-10-03 2008-04-17 Rigaku Corp 熱分析装置のセンサユニットおよびその製造方法
FR2925163B1 (fr) * 2007-12-12 2010-02-26 Centre Nat Rech Scient Procede et appareil d'analyse thermique
EP2133690B1 (en) * 2008-06-13 2011-03-09 Mettler-Toledo AG Thermoanalytical instrument with dynamic power compensation
EP2214005B1 (en) * 2009-02-03 2019-09-18 Mettler-Toledo GmbH Thermo-Analytical Instrument
US8517600B2 (en) * 2009-10-27 2013-08-27 General Electric Company Deposition sensor based on differential heat transfer resistance
JP5642525B2 (ja) * 2010-02-02 2014-12-17 株式会社日立ハイテクサイエンス 示差走査熱量計
KR101853882B1 (ko) * 2011-01-10 2018-05-02 삼성전자주식회사 생체물질 검사장치 및 그 제어방법
US20120238623A1 (en) * 2011-03-14 2012-09-20 Chandraratna Roshantha A Inflammation and Autoimmune Disorder Treatment using RARa Selective Agonists
CN103732231B (zh) 2011-06-24 2020-04-10 格里生物公司 炎性病症的预防和治疗
WO2013019653A1 (en) * 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Compounds and methods
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
AU2012352149B2 (en) 2011-12-13 2017-06-01 Io Therapeutics, Inc. Autoimmune disorder treatment using RXR agonists
MX365321B (es) 2012-06-07 2019-05-29 Los Angeles Childrens Hospital Métodos para el tratamiento de neutropenia mediante agonistas retinoides.
KR20160113302A (ko) 2014-02-18 2016-09-28 칠드런＇스 하스피틀 로스 앤젤레스 호중구감소증을 치료하기 위한 조성물 및 방법
EP2921833B1 (de) * 2014-03-18 2016-12-28 Mettler-Toledo GmbH Thermoanalytischer Sensor und Verfahren zu dessen Herstellung
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
CN114712504A (zh) 2014-12-09 2022-07-08 Gri生物有限公司 炎性病况的预防和治疗
US20160317654A1 (en) * 2015-03-09 2016-11-03 Kings College London Combination therapy with rar alpha agonists for enhancing th1 response
IL309066A (en) 2015-03-31 2024-02-01 Syros Pharmaceuticals Inc Methods of stratifying patients for treatment with retinoic acid receptor-α agonists
JP2018533622A (ja) 2015-09-28 2018-11-15 アズーラ オフサルミックス エルティーディー． マイボーム腺の脂質分泌を増加させるためのチオールおよびジスルフィド含有薬剤
CN108289958A (zh) 2015-10-31 2018-07-17 Io治疗公司 使用rxr激动剂和甲状腺激素的组合治疗神经系统紊乱
ES2898676T3 (es) * 2015-11-25 2022-03-08 Io Therapeutics Inc Agonistas selectivos de rar-alfa resistentes a CYP26 en el tratamiento del cáncer
KR20180121983A (ko) 2016-03-10 2018-11-09 아이오 테라퓨틱스, 인크. Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 근육 질환의 치료
CN109310769B (zh) 2016-03-10 2022-07-05 Io治疗公司 用rxr激动剂与甲状腺激素的组合的自身免疫疾病的治疗
US9868994B2 (en) 2016-04-08 2018-01-16 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-α agonists
BR112018070547A2 (pt) 2016-04-08 2019-02-12 Syros Pharmaceuticals, Inc. agonistas de rara para o tratamento de aml e mds
JP6919970B2 (ja) 2016-04-14 2021-08-18 アズーラ オフサルミックス エルティーディー． マイボーム腺機能不全の処置において使用される二硫化セレン組成物
CN108078966B (zh) * 2016-11-22 2021-08-17 厦门大学 芳香硝基乙烯类化合物的用途
KR20200029543A (ko) * 2017-07-13 2020-03-18 아이오 테라퓨틱스, 인크. 암 면역요법을 위해 면역 조절제와 조합된 수용체 서브타입 및 기능 선택적 레티노이드 및 렉시노이드 화합물
CN111148514A (zh) * 2017-08-31 2020-05-12 Io治疗公司 与免疫调节剂联合应用于癌症免疫治疗的rar选择性激动剂
WO2019060600A1 (en) 2017-09-20 2019-03-28 Io Therapeutics, Inc. TREATMENT OF DISEASE WITH ESTERS OF SELECTIVE RXR AGONISTS
PT3818050T (pt) * 2018-07-05 2023-07-04 Bayer Ag Tiofenocarboxamidas substituídas e análogos como agentes antibacterianos
US11474054B2 (en) * 2018-10-22 2022-10-18 Equistar Chemicals, Lp Temperature control apparatuses and methods
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
WO2020263960A1 (en) * 2019-06-28 2020-12-30 Carl Wagner Compositions comprising a retinoid x receptor (rxr) agonist, a retinoic acid receptor (rar) agonist, or a dual rxr/rar agonist
WO2021140417A2 (en) 2020-01-10 2021-07-15 Azura Ophthalmics Ltd. Instructions for composition and sensitivity
US12117349B2 (en) * 2021-03-30 2024-10-15 Tdk Corporation Sensor system, sensor array and process of using the sensor system
KR20240027782A (ko) * 2021-12-02 2024-03-04 상하이 키젠트 파마슈티컬 컴퍼니 리미티드 방향족 화합물, 이의 약학 조성물 및 이의 용도
MX2024006978A (es) 2021-12-07 2024-07-19 Io Therapeutics Inc Uso de un agonista de rxr y taxanos en el tratamiento de cáncer her2+.
KR20240115316A (ko) 2021-12-07 2024-07-25 아이오 테라퓨틱스, 인크. 약물 내성 her2+ 암 치료에서의 rxr 작용제의 용도
EP4543430A1 (en) 2022-06-27 2025-04-30 IO Therapeutics, Inc. Synthesis of tetrahydronaphthalenols and uses thereof
CN119462628B (zh) * 2024-09-29 2025-11-18 湖北大学 一种rar protac化合物、药物组合物、制备方法及应用

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067975A (en) * 1975-08-04 1978-01-10 Yu Ruey J Treatment of psoriasis with 6-aminonicotinamide and thionicotinamide
US4085091A (en) 1976-12-16 1978-04-18 E. I. Dupont De Nemours And Company Thermally stable, rigid polyesters from thermally stable, rigid dibasic acids and aromatic dihydroxy compounds
US4111717A (en) * 1977-06-29 1978-09-05 Leeds & Northrup Company Small-size high-performance radiation thermopile
US4326055A (en) 1977-12-22 1982-04-20 Hoffmann-La Roche Inc. Stilbene derivatives
FR2440353A1 (fr) * 1978-11-03 1980-05-30 Science Union & Cie Nouveaux arylethanols, leurs procedes d'obtention et leur emploi comme medicament
EP0047817A3 (de) 1980-08-14 1982-05-26 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Hydrierte Naphthaline, deren Herstellung und Verwendung sowie derartige Naphthaline enthaltende Gemische
CH651034A5 (de) 1982-05-12 1985-08-30 Hoffmann La Roche Chroman-, thiochroman- oder 1,2,3,4-tetrahydrochinolinderivate und ihre verwendung als arzneimittel-wirkstoffe.
DK158947C (da) 1982-07-06 1991-01-21 Hoffmann La Roche Tetrahydronaphthalin-,benzofuran- og benzothiophenderivater, fremstilling og anvendelse deraf samt rodenticid indeholdende saadanne derivater
US4794188A (en) * 1982-12-01 1988-12-27 Usv Pharmaceutical Corporation Certain unsymmetrical quinolinyl ethers having anti-inflammatory and anti-allergic activity
EP0130795B1 (en) 1983-07-05 1988-11-23 Pfizer Inc. Carboxylic acid derivatives useful for inhibiting the degradation of cartilage
EP0155940A1 (en) 1983-08-08 1985-10-02 Sri International Benzonorbornenyl, benzopyranyl and benzothiopyranyl retinoic acid analogues
FR2562539B1 (fr) 1984-04-06 1987-04-17 Chauvin Blache Lab Nouveaux derives de l'acide vinyl-4 benzoique, leur procede de preparation et leurs applications en therapeutique et comme ligands
US4826984A (en) 1984-04-09 1989-05-02 The Board Of Regents For The Oklahoma Agricultural And Mechanical College Acting For And On Behalf Of Oklahoma State University Heteroarotinoid compounds as anticancer agents
JPS60222445A (ja) 1984-04-19 1985-11-07 Yoshitomi Pharmaceut Ind Ltd フタル酸化合物
EP0170105B1 (en) * 1984-07-07 1990-10-17 Koichi Prof. Dr. Shudo Benzoic acid derivatives
JPS6122046A (ja) 1984-07-07 1986-01-30 Koichi Shiyudo スチルベン誘導体
LU85544A1 (fr) 1984-09-19 1986-04-03 Cird Derives heterocycliques aromatiques,leur procede de preparation et leur application dans les domaines therapeutique et cosmetique
DE3434946A1 (de) 1984-09-22 1986-04-03 Basf Ag, 6700 Ludwigshafen Diarylacetylene, ihre herstellung und verwendung
DE3434947A1 (de) 1984-09-22 1986-04-03 Basf Ag, 6700 Ludwigshafen Isoxazolcarbonsaeure-derivate, ihre herstellung und verwendung
DE3434942A1 (de) 1984-09-22 1986-04-03 Basf Ag, 6700 Ludwigshafen Tetralin-derivate, ihre herstellung und verwendung
HU194405B (en) * 1985-05-10 1988-01-28 Magyar Optikai Muevek Temperature control system for testing thermic phase transformations
DE3529489A1 (de) * 1985-08-16 1987-02-26 Max Planck Gesellschaft Verfahren und einrichtung zum bestimmen der waermekapazitaet einer probe
IL80270A0 (en) 1985-10-11 1987-01-30 Cird Naphthalene derivatives,their preparation and pharmaceutical compositions containing them
DE3602473A1 (de) 1986-01-28 1987-07-30 Basf Ag Vinylphenolderivate, ihre herstellung und verwendung
LU86351A1 (fr) 1986-03-12 1987-11-11 Oreal Composes benzopyrannyl et benzothiopyrannyl benzoiques,leur procede de preparation et leur utilisation en cosmetique et en medecine humaine et veterinaire
DE3615157A1 (de) 1986-05-05 1987-11-12 Schwabe Willmar Gmbh & Co 5-arylalkyl-4-alkoxy-2(5h)-furanone, zwischenprodukte und verfahren zu ihrer herstellung sowie ihre anwendung als therapeutische wirkstoffe
ZW6587A1 (en) 1986-05-13 1987-12-02 Hoffmann La Roche Tetrahydro naphthanline derivatives
ZW7487A1 (en) 1986-05-23 1987-12-16 Hoffmann La Roche Tetrahydronaphthaline and indane derivatives
ZW10287A1 (en) 1986-07-15 1988-01-13 Hoffmann La Roche Tetrahydronaphthaline and indane derivatives
US4739098A (en) 1986-09-22 1988-04-19 Allergan, Inc. Ethynylphenyl-containing retinoic acid derivatives
NZ222968A (en) 1986-12-24 1990-05-28 Allergan Inc Ethynylheteroaromatic derivatives and medicaments
US4927947A (en) 1986-12-24 1990-05-22 Allergan, Inc. Ethynylheteroaromatic-acids having retinoic acid-like activity
US5089509A (en) 1988-09-15 1992-02-18 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
CA1305480C (en) 1987-03-20 1992-07-21 Roshantha A.S. Chandraratna Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5264578A (en) 1987-03-20 1993-11-23 Allergan, Inc. Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity
US5234926A (en) 1987-03-20 1993-08-10 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US4810804A (en) 1987-03-26 1989-03-07 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a heterobicyclic group having retinoid-like activity
ZA885192B (en) 1987-08-19 1989-04-26 Hoffmann La Roche Pharmaceutical preparations
CA1298309C (en) 1987-11-06 1992-03-31 Michael Klaus Benzocycloheptene derivatives
US5231113A (en) 1988-04-11 1993-07-27 Allergan, Inc. Tetralin esters of phenols or benzoic acids having retinoid like activity
KR0139216B1 (ko) 1988-04-11 1998-05-01 제임스 엠. 캐내지 레티노이드 유사활성을 갖는 페놀 또는 벤조산의 테트랄린 에스테르
US4895868A (en) 1988-06-29 1990-01-23 Allergan, Inc. Thiochroman esters of phenols and terephthallates having retinoid-like activity
US5015658A (en) 1988-06-29 1991-05-14 Allergan, Inc. Thiochroman esters of phenols and terephthallates having retinoid-like activity
AU626881B2 (en) * 1988-07-14 1992-08-13 F. Hoffmann-La Roche Ag Benzofused heterocyclics used as pharmaceuticals
US5068252A (en) 1989-07-26 1991-11-26 Allergan, Inc. Methods of using phenylethenyl compounds having retinoid-like activity
US4992468A (en) 1989-07-26 1991-02-12 Allergan, Inc. Phenylethenyl compounds having retinoid-like activity
US5183827A (en) 1989-09-19 1993-02-02 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5272156A (en) 1989-09-19 1993-12-21 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5162546A (en) 1989-09-19 1992-11-10 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5399561A (en) 1989-09-19 1995-03-21 Allergan, Inc. Acetylenes disubstituted with a phenyl or heteroaryl group and a 2-oxochromanyl, 2-oxothiochromanyl or 2-oxo-1,2,3,4-tetrahydro-quinolinyl group having retinoid-like biological activity
US5023341A (en) 1989-09-19 1991-06-11 Allergan, Inc. Compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity
US5045551A (en) 1989-09-19 1991-09-03 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5053523A (en) 1989-09-19 1991-10-01 Allergan, Inc. Ethynyl-chroman compounds
US4980369A (en) 1989-09-19 1990-12-25 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl or thiochromanyl group having retinoid-like activity
US5248777A (en) 1989-09-19 1993-09-28 Allergan, Inc. Process and intermediates for preparing compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity
US5175185A (en) 1989-12-29 1992-12-29 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a substituted phenyl group having retinoid like activity
US5264456A (en) 1989-12-29 1993-11-23 Allergan, Inc. Acetylenes disubstituted with a furyl group and a substituted phenyl group having retinoid like activity
US5006550A (en) 1989-12-29 1991-04-09 Allergan, Inc. Chroman esters of phenols and benzoic acids having retinoid-like activity
US5013744B1 (en) 1989-12-29 1994-09-20 Allegran Inc Acetylenes disubstituted with a pyridinyl group and a substituted phenyl group having retinoid like activity
US5202471A (en) 1990-02-06 1993-04-13 Allergan, Inc. Alkyl, alkoxy and thioalkoxy substituted diphenyl acetylenes having retinoid like activity
IL97872A (en) 1990-04-16 1996-07-23 Rhone Poulenc Rorer Int Pharmaceutical compositions containing styryl-substituted monocylic and bicyclic heteroaryl compounds which inhibit egf receptor tyrosine kinase and a compounds of this type
LU87821A1 (fr) 1990-10-12 1992-05-25 Cird Galderma Composes bi-aromatiques,et leur utilisation en medecine humaine et veterinaire et en cosmetique
CA2101160A1 (en) 1991-02-13 1992-08-14 Roshantha A. Chandraratna Chroman and thiochromans with phenylethynyl substituents at the 7-position having retinoid-like biological activity
US5134159A (en) 1991-03-26 1992-07-28 Allergan, Inc. 7-chromanyl esters of phenols and benzoic acids having retinoid-like activity
AU652830B2 (en) 1991-03-26 1994-09-08 Allergan, Inc. Chromans and thiochromans with heteroarylethynyl substituents at the 7-position having retinoid-like biological activity
FR2676440B1 (fr) * 1991-05-15 1993-07-30 Cird Galderma Nouveaux composes aromatiques derives d'imine, leur procede de preparation et leur utilisation en medecine humaine et veterinaire ainsi qu'en cosmetique.
ATE208194T1 (de) * 1991-08-23 2001-11-15 Salk Inst For Biological Studi Verwendung von selektiven liganden zur behandlung von hormonansprechenden krankheitzuständen
US5326898A (en) 1992-02-11 1994-07-05 Allergan, Inc. Substituted phenylethenyl compounds having retinoid-like biological activity
JP3499553B2 (ja) 1992-02-11 2004-02-23 アラーガン、インコーポレイテッド レチノイド様生物学的活性を有するヘテロアリール置換フェニルエテニル化合物
US5420145A (en) * 1993-03-22 1995-05-30 Koichi Shudo Carboxylic acid derivative
US5324840A (en) 1992-06-11 1994-06-28 Allergan, Inc. Method of treatment with compounds having retinoid-like activity and reduced skin toxicity and lacking teratogenic effects
JPH0672866A (ja) * 1992-07-02 1994-03-15 Chugoku Igakuka Gakuin Yakubutsu Kenkyusho 分化誘導剤
US5288147A (en) * 1992-11-09 1994-02-22 Ta Instruments, Inc. Thermopile differential thermal analysis sensor
US5455265A (en) 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
US5399586A (en) * 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
EP0619116A3 (en) * 1993-04-05 1994-11-23 Hoechst Japan Use of synthetic retinoids for osteopathy.
US5344959A (en) 1993-05-18 1994-09-06 Allergan, Inc. Tetrahydronaphthyl and cyclopropyl substituted 1,3-butadienes having retinoid-like activity
US5475022A (en) 1993-10-18 1995-12-12 Allergan, Inc. Phenyl or heteroaryl and tetrahydronaphthyl substituted diene compounds having retinoid like biological activity
WO1995017889A1 (en) * 1993-12-29 1995-07-06 Kowa Tekuno Sachi Co., Ltd. Therapeutic composition for hyperparathyroidism of patient subjected to artificial dialysis
US5470999A (en) 1993-12-30 1995-11-28 Allergan, Inc. Cyclohexene and bicyclic aromatic substituted ethyne compounds having retinoid-like biological activity
US5426118A (en) 1993-12-30 1995-06-20 Allergan, Inc. [4-(1,2-epoxycyclohexanyl)but-3-en-1-ynyl]aromatic and heteroaromatic acids and derivatives having retinoid-like biological activity
US5451605A (en) 1993-12-30 1995-09-19 Allergan, Inc. 1,2-epoxycyclohexanyl and bicyclic aromatic substituted ethyne compounds having retinoid-like biological activity
CA2138000A1 (en) 1994-01-03 1995-07-04 John E. Starrett, Jr. Retinoid-like compounds
FR2722985B1 (fr) * 1994-07-27 1996-09-13 Cird Galderma Nouvelles compositions a base d'un melange synergetique entre au moins un ligand specifique des rxrs et au moins un ligand specifique de rar-x ou de vdr, et leurs utilisations
US5498755A (en) 1994-08-23 1996-03-12 Chandraratna; Roshantha A. Disubstituted aryl and heteroaryl imines having retinoid-like biological activity
US5498795A (en) 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
US5489584A (en) 1994-12-29 1996-02-06 Allergan, Inc. Acetylenes disubstituted with a 5-amino or substituted 5-amino substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5750515A (en) * 1995-04-10 1998-05-12 Taiho Pharmaceutical Co., Ltd. Cancer metastasis inhibitor
FR2733564B1 (fr) * 1995-04-27 1997-06-20 Peugeot Agencement d'amortissement par laminage d'un fluide et systeme de suspension, notamment de vehicule automobile, equipe d'un tel agencement d'amortissement
US5779363A (en) * 1995-09-27 1998-07-14 The Johns Hopkins University Capillary calorimetric cell and method of manufacturing same
US5965606A (en) * 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
US5813763A (en) * 1996-10-11 1998-09-29 Microcal Incorporated Ultrasensitive differential microcalorimeter
JP2000503407A (ja) * 1996-11-01 2000-03-21 ティーエイ インストゥルメンツ，インコーポレイティド 微分走査カロリーメータ
US6079873A (en) * 1997-10-20 2000-06-27 The United States Of America As Represented By The Secretary Of Commerce Micron-scale differential scanning calorimeter on a chip
JPH11160226A (ja) * 1997-12-01 1999-06-18 Mitsubishi Chemical Corp 腐蝕センサーの作成方法
JP3137605B2 (ja) * 1998-07-14 2001-02-26 セイコーインスツルメンツ株式会社 熱流束型示差走査熱量計

Also Published As

Publication number Publication date
US20020085615A1 (en) 2002-07-04
US6610744B2 (en) 2003-08-26
HUP0001643A2 (hu) 2001-05-28
CN1211180A (zh) 1999-03-17
US5965606A (en) 1999-10-12
IL125121A0 (en) 1999-01-26
RU2191009C2 (ru) 2002-10-20
CZ206998A3 (cs) 1999-04-14
WO1997024116A3 (en) 1997-11-13
JP2000502707A (ja) 2000-03-07
NZ326155A (en) 2000-08-25
US6508585B2 (en) 2003-01-21
AU710483B2 (en) 1999-09-23
HUP0001643A3 (en) 2003-01-28
AU1345097A (en) 1997-07-28
US20020077360A1 (en) 2002-06-20
CA2241758A1 (en) 1997-07-10
WO1997024116A2 (en) 1997-07-10
EP0869782A2 (en) 1998-10-14
MX9805282A (es) 1998-10-31
PL327627A1 (en) 1998-12-21
KR19990076814A (ko) 1999-10-15
US6534544B1 (en) 2003-03-18

Similar Documents

Publication Publication Date Title
BR9612318A (pt) &#34;métodos de tratamento com compostos tendo atividade especìfica ou seletiva sobre o receptor de raralfa&#34;
TR200101969T2 (tr) Enflamasyon tedavisi için sübstitüe edilmiş benzopiran analogları.
BR9803596A (pt) Derivados do resorcinol.
BR9712491A (pt) Composições cosméticas
BR0112044A (pt) Embalagem de produtos medicinais para terapia de erradicação
ES2121404T3 (es) Procedimiento para la preparacion de trihidrato del (2r,3s)-3-terc-butoxicarbonilamino-2-hidroxi-3-fenilpropionato de 4-acetoxi-2alfa-benzoiloxi-5beta,20-epoxi-1,7beta,10beta-trihidroxi-9-oxo-tax-11-en-13alfa-ilo.
ES2138691T3 (es) Procedimiento para la obtencion de derivados de n-acil-5-fluorocitidina.
BR0112591A (pt) Derivados de acridina e sua aplicação como medicamento
ES2191208T3 (es) Oxiimino-pregnano-carbolactonas.
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
EA200100154A1 (ru) Бензоциклогептены, способ их получения, содержащие их фармацевтические препараты и их применение для получения лекарственных средств
BG100930A (bg) Фармацевтични състави и лекарствени средства за профилактика и лечение на ендотелиални нарушения
SE9802208D0 (sv) Novel compounds
ES2133412T3 (es) 2&#39;,5&#39;-oligoadenilato-2&#39;,3&#39;-ciclofosfatos y 2&#39;,5&#39;-oligoadenilatos con actividad sobre el virus papiloma.
BR9916440A (pt) Composição tópica, processo cosmético para clareamento de pele humana, e, uso do ácido linoleico conjugado e/ou derivados do mesmo
PT1009436E (pt) Derivado de acridina para aumentar a biodisponibilidade oral do taxol
BR9712141A (pt) Aplicação de 1-hifróxi-2-piridonas para tratamento de infecções cutâneas.
BR0112807A (pt) Derivados de indol e sua aplicação como medicamento
BR0009211A (pt) Derivados de resorcinol
MX9604765A (es) Derivados de 5-heterociclico 1,5-benzodiazepinas que modulan la cck o gastrina.
BR9915955A (pt) Composição cosmética para cuidado com a pele, processo cosmético para tratar uma pele envelhecida e uso de 4- cromanona
ES2139332T3 (es) Procedimiento para la preparacion del trihidrato del (2r,3s)-3-benzoilamino-2-hidroxi-3-fenilpropionato de 4,10-diacetoxi-2alfa-benzoiloxi-5beta,20-epoxi-1,7beta-dihidroxi-9-oxo-tax-11-en-13alfa-ilo.
FR2692574B1 (fr) Derives hydroxy-4 benzenethio, leur preparation ainsi que leur utilisation pour la preparation de derives aminoalkoxybenzenesulfonyles.
AR008860A1 (es) Empleo de 1-hidroxi-2-piridonas para el tratamiento de la dermatitis seborreica
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: ALLERGAN (US)

Free format text: ALTERADO DE : VISION PHARMACEUTICALS L.P.

B25G Requested change of headquarter approved

Owner name: ALLERGAN (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 000922-RJ, DE 07/01/2004

B25A Requested transfer of rights approved

Owner name: ALLERGAN, INC. (US)

Free format text: TRANSFERIDO DE: ALLERGAN

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 6A, 7A E 8A ANUIDADES.